Innovation Partners
Weekly founder insights · Japan → U.S.
Partnerships
Where clinical, industry and Japan–U.S. relationships can move your plan forward.
For Japanese medical-device, diagnostics and regulated medical-AI founders entering the United States.
Showing the dated edition below. Weekly updates are being connected.
- 2027 applications open; deadline December 1, 2026 · Upcoming
MedTech Innovator 2027 offers a competitive U.S. partner route
What changed: MedTech Innovator’s five-month 2027 program accepts worldwide medical-device, diagnostic and digital-health applicants targeting the U.S., connecting selected companies with strategic and clinical, regulatory and reimbursement experts.
Founder implication · interpretation: Japanese founders should articulate a specific U.S. use case and partner need before applying.
Next action: Prepare a commercialization plan, confirm leadership capacity for participation and apply by December 1; an information session is listed for October 27.
What to confirm: The application opening date and precise deadline time were not published in the retrieved page. The October 27 session is at 12 p.m. Eastern / 9 a.m. Pacific. Selection is competitive; introductions do not guarantee commercial agreements.
Primary sources:MedTech Innovator · 2027 application and eligibility information - September launch; current selective application route · Ongoing · 2026-09-03
Mayo Clinic Platform adds a multiyear AI development pathway
What changed: Mayo Clinic Platform announced a selective multiyear Accelerate pathway with 12 initial AI companies. Its current page describes up to two years of data-environment access, advisors and technical support.
Founder implication · interpretation: Japanese regulated-AI founders can assess whether the available de-identified data supports their evidence question.
Next action: Prepare a data specification and evidence-gap assessment; verify population fit, access rights and contracting terms before seeking an interview.
What to confirm: The current pages display no application deadline or nationality restriction. Entry is selective and does not imply FDA authorization, Mayo clinical adoption or endorsement. This is not a guaranteed prospective-trial program.
- Cohort already selected; next phase planned for mid-October · Upcoming · 2026-08-10
JETRO–TheraNova cohort illustrates readiness for U.S. evidence partners
What changed: JETRO’s five-company Medical Data Utilization cohort with TheraNova is scheduled to enter data generation and validation in mid-October, following research-partner preparation, contracting and IRB work where required.
Founder implication · interpretation: Other Japanese founders can use this sequence to prepare focused requests to U.S. clinical partners.
Next action: Define the study, data source, partner responsibilities, contracting and IRB needs, and the resulting regulatory or adoption milestone.
What to confirm: This cohort is already selected and is not an open application opportunity. Phase dates are prospective as of October 9; the next phase has not been reported as begun. No PBIP role is evidenced.
Primary sources:JETRO · August 10 U.S. evidence cohort announcement